Search results for "Pituitary Neoplasms"

showing 4 items of 34 documents

The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1

2011

Reactivation of the HMGA1 protoncogene is very frequent in human cancer, but still very little is known on the molecular mechanisms leading to this event. Prompted by the finding of putative E2F binding sites in the human HMGA1 promoter and by the frequent deregulation of the RB/E2F1 pathway in human carcinogenesis, we investigated whether E2F1 might contribute to the regulation of HMGA1 gene expression. Here we report that E2F1 induces HMGA1 by interacting with a 193bp region of the HMGA1 promoter containing an E2F binding site surrounded by three putative Sp1 binding sites. Both gain and loss of function experiments indicate that Sp1 functionally interacts with E2F1 to promote HMGA1 expre…

Transcriptional ActivationChromatin ImmunoprecipitationSp1 Transcription FactorBlotting WesternMolecular Sequence DataReal-Time Polymerase Chain ReactionRetinoblastoma ProteinSp1MiceAnimalsHumansPituitary NeoplasmsThyroid NeoplasmsHMGA1a ProteinPituitary NeoplasmRNA MessengerPromoter Regions GeneticCarcinogenesiThyroid NeoplasmHMGA1 promoterMice KnockoutBinding SitesBase SequenceAnimalReverse Transcriptase Polymerase Chain ReactionBinding SiteMutationMutagenesis Site-DirectedTranscriptionE2F1 Transcription FactorHumansp1; carcinogenesis; hmga1 promoter; transcription
researchProduct

Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs

2020

Pituitary carcinomas (PCa) are extremely rare, indistinguishable from pituitary adenomas on histopathological grounds and have a poor prognosis. Most PCa start as PRL or ACTH secreting tumors in males, with relapsing invasive behaviour, refractoriness to medical and radiotherapy and increasing hormonal levels. The presence of distant metastases is still required for the diagnosis of PCa. The association with genetic endocrine diseases must be taken into account, since it adds further risk of evolution towards malignancy. Intradural spinal metastases have also been reported, so a complete craniospinal MR evaluation is recommended, when clinically indicated. We report a case of PCa, associate…

lcsh:Medical physics. Medical radiology. Nuclear medicinePathologymedicine.medical_specialtymedicine.medical_treatmentlcsh:R895-920Neoplasm metastasisTentorium cerebelliPituitary neoplasmPituitary neoplasmsMalignancyArticle030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePituitary adenomamedicineEndocrine systemRadiology Nuclear Medicine and imagingMEN1Ki-67 antigenNeoplasm metastasiPituitary carcinomabusiness.industryMagnetic resonance imaging MRISettore MED/37 - Neuroradiologiamedicine.diseasePituitary adenomaRadiation therapy030220 oncology & carcinogenesisPituitary neoplasms Pituitary carcinoma Pituitary adenoma Neoplasm metastasis Ki-67 antigen Magnetic resonance imaging MRIPituitary carcinomaSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessEuropean Journal of Radiology Open
researchProduct

First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors

2021

AbstractAlthough non-functioning pituitary tumors are frequent, diagnostic and therapeutic concepts are not well standardized. We here present the first German multidisciplinary guideline on this topic. The single most important message is to manage the patients by a multidisciplinary team (consisting at least of an endocrinologist, a neurosurgeon, and a (neuro-) radiologist). The initial diagnostic work-up comprises a detailed characterization of both biochemical (focusing on hormonal excess or deficiency states) and morphological aspects (with magnetic resonance imaging of the sellar region). An ophthalmological examination is only needed in presence of symptoms or large tumors affecting …

medicine.medical_specialtyAdenomaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedizin030209 endocrinology & metabolism03 medical and health sciencesTherapeutic approach0302 clinical medicineEndocrinologyGermanyInternal MedicinemedicineHumansPituitary NeoplasmsNeuroradiologyPatient Care Teammedicine.diagnostic_testbusiness.industryPituitary tumorsMagnetic resonance imagingGeneral MedicineGuidelinemedicine.diseaseMagnetic Resonance ImagingRadiation therapyPractice Guidelines as TopicRadiologyNeurosurgerybusiness030217 neurology & neurosurgeryExperimental and Clinical Endocrinology & Diabetes
researchProduct

Longitudinal Study on Growth and Body Mass Index before and after Diagnosis of Childhood Craniopharyngioma

2004

Abstract We analyzed whether childhood craniopharyngioma predisposes to obesity and growth impairment. Height/length, body mass index (BMI), and hypothalamic involvement were evaluated in 90 patients at standardized ages and time points before, after, and at the time of diagnosis. Relevant decreases in height sd score (SDS) started at 10–12 months of age and persisted until diagnosis of childhood craniopharyngioma. Relevant increases in BMI SDS were detectable between 4 and 5 yr of age. Postoperative BMI SDS (yr 1–6) had a weak positive correlation with BMI SDS at the time of diagnosis. In linear regression analysis, hypothalamic tumor involvement (P < 0.001), ponderal index at birth…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryHypothalamusPituitary neoplasmBiochemistryBody Mass IndexCraniopharyngiomaChild DevelopmentEndocrinologyRisk FactorsInternal medicinemedicineHumansNeoplasm InvasivenessPituitary NeoplasmsLongitudinal StudiesObesityRisk factorGrowth DisordersRetrospective Studiesbusiness.industryBody WeightBiochemistry (medical)Childhood CraniopharyngiomaInfantmedicine.diseaseObesityBody HeightCraniopharyngiomaEndocrinologyEl NiñoMultivariate AnalysisHypothalamic NeoplasmDisease SusceptibilitybusinessBody mass indexThe Journal of Clinical Endocrinology & Metabolism
researchProduct